Amgen Inc. AMGN
Healthcare · Drug Manufacturers - General · United States · S&P 500
Based on the available data, Amgen Inc. gets an algorithmic score of 70/100. It trades at 423.64 $, with a bullish technical trend (RSI 60.9) and 29.5% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (91.5%): generates strong profit on equity.
- High net margin (23.0%): pricing power / competitive advantage.
- Sustained revenue growth (11.8% compound annual).
- Low beta (0.26): defensive profile.
Weaknesses
- High leverage (debt/equity 490%): rate-sensitive.
Fundamentals
| P/E | 26.31 |
| Forward P/E | 17.33 |
| PEG | 2.45 |
| P/B | 19.59 |
| EV/EBITDA | 15.77 |
| P/S | 6.01 |
| ROE % | 91.47 |
| ROA % | 8.67 |
| Gross margin % | 71.89 |
| Operating margin % | 35.55 |
| Net margin % | 22.95 |
| Revenue growth % (y/y) | 9.50 |
| Earnings growth % (y/y) | 64.90 |
| Revenue CAGR % | 11.77 |
| Earnings CAGR % | 5.58 |
| Debt/Equity % | 490.28 |
| Current ratio | 1.37 |
| FCF yield % | 3.54 |
| Dividend yield % | 2.38 |
| Payout % | 60.87 |
Returns
| 1 month | -2.0 % |
| 3 months | +17.7 % |
| 6 months | +23.0 % |
| YTD | +31.9 % |
| 1 year | +59.5 % |
| 3 years | +73.1 % |
| 5 years | +129.8 % |
Risk
| 1-year volatility | 29.5 % |
| Beta | 0.26 |
| 5-year max drawdown | -24.9 % |
| Sharpe 1A | 1.60 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.